Syndax Pharmaceuticals Investor Relations Material

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops therapies for the treatment of cancer. The Company is engaged in the development and commercialization of novel medicines for cancer. The Company's pipeline includes BTG4-L1, a small molecule that has shown preclinical activity in treating multiple tumor types including breast, ovarian, prostate and central nervous system cancers; and SID418, which has demonstrated remarkable antiviral activity against Ebola virus and related filoviruses. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.